Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
South Korea
Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do Yonsei University Severance Hospital, Seoul The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul Ajou University Hospital, Suwon